Accelevir Diagnostics LLC Profile last edited on: 10/21/2021
CAGE: 7FL22
UEI: F6SKM7YHCUS7
Business Identifier: Assays for latent HIV 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Baltimore City
Congr. District: 07
County: Baltimore City
Public Profile
Spun out of Johns Hopkins, Accelevir Diagnostics is developing new assays for latent HIV. More than 35 million people are living the HIV/AIDS. Current antiretroviral drugs halt, but do not eliminate the virus in people who are infected. Instead, HIV persists in a quiescent, or latent form. New therapeutics are being developed to eliminate this latent virus with the goal of curing the infection: creating innovative assays and technologies to support this therapeutic development effort.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2022 | 2 | NIH | $600,000 | |
| Project Title: IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials | ||||
| 2021 | 1 | NIH | $300,000 | |
| Project Title: HIV-1 EnvLRS: a scalable, sequence-based assay for in-depth assessment of HIV-1 bNAb resistance | ||||
| 2020 | 1 | NIH | $299,975 | |
| Project Title: The Objective of This Contract Is to Adapt the Ipda for the Measurement of Latent HIV-1 for Individuals with HIV-1 Viral Genetic Subtype Crf-1_ae. | ||||
| 2020 | 1 | NIH | $300,000 | |
| Project Title: Development of Intact Proviral Dna Assays for SIV and ShIV | ||||
| 2019 | 2 | NSF | $1,424,533 | |
| Project Title: Development and optimization of a new molecular test to quantify latent HIV-1 in samples from HIV-1 infected individuals. | ||||
Key People / Management
Gregory M Laird
Company News
There are no news available.
